Visit our new Alternative Investment section.Click here

Less Ads, More Data, More Tools Register for FREE

AIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflows

Thu, 09th Jan 2025 09:53

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 90% at 2.28 pence, 12-month range 0.82p-3.00p. The drug discovery and development company hails "groundbreaking advancements" in preclinical research in the autoimmune diseases space. "We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates potential new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies," Chief Executive Officer Tim McCarthy says. The firm is "not at this time releasing detailed data" on the findings as they are part of an ongoing expansion of its intellectual property portfolio. However, it did say the findings pave the way for "earlier and more accurate diagnostics" and make it easier to spot patients who are more likely to respond to the P140 treatment. The findings also suggest improved monitoring of treatment response.

----------

Cirata PLC, up 26% at 26.90p, 12-month range 19.05p-85.00p. The software solutions provider says it rounded off 2024 with the "strongest bookings quarter" since the second-quarter of 2022. Bookings in the final-quarter of 2024 total USD3.0 million, improving from USD2.7 million a year prior and USD1.7 million in the third-quarter. Annual bookings amount to USD7.1 million for 2024, fading from USD7.2 million for 2023.

----------

AIM - LOSERS

----------

Impax Asset Management Group PLC, down 3.4% at 234.34p, 12-month range 220.50p-559.00p. The firm reports assets under management decline 8.3% quarter-on-quarter to GBP34.11 billion at its December 31 first-quarter end. "This quarter we saw relatively high outflows, notably the closure of our smaller mandate with St James's Place and redemptions driven by industry consolidation in our institutional channel in the Asia-Pacific region," CEO Ian Simm says. "More positively, we have continued to see a slow-down in outflows from our largest European distribution partner, BNP Paribas Asset Management, and from our US mutual funds." It reports net outflows of GBP2.42 billion for the period, as well as a GBP660 million hit from the performance, market movement, and foreign exchange.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Immupharma Cirata Impax Asset Management

Shares in this article

Related News

WINNERS & LOSERS: Ramsdens ups profit view; Reach revenue falls
5 days ago

WINNERS & LOSERS: Ramsdens ups profit view; Reach revenue falls

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.

Cirata reports first cash flow positive quarter; reaffirms outlook
14 Apr 2026

Cirata reports first cash flow positive quarter; reaffirms outlook

(Alliance News) - Cirata PLC on Tuesday backed its full-year outlook as it posted its first ever cash flow positive quarter.

Impax reports 8pc decline in assets under management
10 Apr 2026

Impax reports 8pc decline in assets under management

(Sharecast News) - Impax Asset Management reported an 8.0% decline in assets under management over the second quarter of its financial year on Friday,...